Medical Cannabis As A Reliever To Chronic Pain Is Seen As One Alternative To Addictive Opi-oids, According to New Research Study; Electromedical Technologies, Inc.’s (OTCQB: EMED) Devices Offer FDA Cleared Treatment For Acute Pain
A new study of 580 participants in a Toronto-based study, as reported by Practical Pain Management (PPM) Magazine, finds that medical cannabis is one alternative to opioid-addicting pain killer drugs in the treatment of acute and chronic pain. Medical cannabis in particular was found to be a safe alternative to prescription drugs. It specifies that patients must be under the care of healthcare professionals. The line of WellnessPro Plus™ devices by Electromedical Technologies, Inc. (OTCQB: EMED) are FDA-cleared and play an important role in relieving acute and chronic pain.
The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).
Medical Cannabis As A Reliever To Chronic Pain Is Seen As One Alternative To Addictive Opioids, According to New Research Study; Electromedical Technologies, Inc.’s (OTCQB: EMED) Devices Offer FDA Cleared Treatment For Acute Pain
The Canadian study in the new issue of Practical Pain Management (PPM) Magazine documents that Medical Marijuana has a role to play in the treatment of chronic pain, especially as an alternative from opioid-addicting prescription pharmaceuticals.
Electromedical Technologies, Inc. (OTCQB: EMED) sees so much demand for its WellnessPro Plus devices in 2021 that it has built up inventory of the devices in late 2020 to prepare for that strong reaction from medical practitioners and distributors.
COVID-19 Pandemic Plays A Role
The heightened demand for EMED’s WellnessPro Plus devices also stems from the impact of the COVID-19 pandemic. More pain-suffering patients are home bound and require a specialized device to provide treatment relief from acute and chronic pain. These offer non-invasive and non-addicting treatments to patients. Medical Cannabis As A Reliever To Chronic Pain Is Seen As One Alternative To Addictive Opioids, According to New Research Study; Electromedical Technologies, Inc.’s (OTCQB: EMED) Devices Offer FDA Cleared Treatment For Acute Pain.
Goldman Small Cap Research Report Projects EMED Will Reach $17 Million By 2022
A new Goldman Small Cap Research report projects EMED conservatively will reach $17 million in volume by 2022, and perhaps as high as $22 million with unit sales of its devices that year reaching 80,000 or 90,000 units. Goldman Small Cap Research projected EMED’s FDA cleared WellnessPro Plus device will exponentially grow in sales. Medical Cannabis As A Reliever To Chronic Pain Is Seen As One Alternative To Addictive Opioids, According to New Research Study; Electromedical Technologies, Inc.’s (OTCQB: EMED) Devices Offer FDA Cleared Treatment For Acute Pain.
Telemedicine Like Remote Portal Feature
The analysis is especially bullish about the sales of the to-be-introduced in late 2021 after an anticipated FDA clearance of the WellnessPlus POD, which features a remote monitoring portal. The telemedicine-like remote portal will enable physicians and technicians to monitor in real time a remote view of therapy effectiveness — a trend as medical facilities are stressed due to COVID-19. The FDA has just issued emergency use authorizations for remote devices.
The WellnessPlus POD unit will be marketed in late 2021
The Goldman report is especially bullish on the new smaller but feature intensive WellnessPllus POD device. A smaller and less costly device, the POD model offers staff a special feature: a portal that enables supervising staff the ability to monitor pain relief treatment in real time. It permits providers to monitor from another location how a patient is receiving pain relief from the device. In a time of home-bound pandemic suffering patients, this is an important new feature.
Anticipating More Medical Practitioners And Distributors, EMED Invests In More Year-End Inventory
Electromedical Technologies, Inc. (OTCQB: EMED) Has Built More WellnessPro Plus™ device inventory for an anticipated accelerated demand in 2021 for the product. As an alternative to opioid-addicting pharmaceuticals, the device solves acute and chronic pain for patients. Medical Cannabis As A Reliever To Chronic Pain Is Seen As One Alternative To Addictive Opioids, According to New Research Study; Electromedical Technologies, Inc.’s (OTCQB: EMED) Devices Offer FDA Cleared Treatment For Acute Pain.
Demand For Telemedicine Devices Spikes During Rise In COVID-19 Patients
The use of remote monitoring devices enables medical facilities to provide treatments for patients and offer real time monitoring by medical providers. The Goldman report projects that Electromedical Technologies, Inc. (OTCQB: EMED) could sell up to 80,000-90,000 units in 2022 with a premium portal feature that could provide remote monitoring of patient treatment and drive 2022 volume as high as $22 million. Goldman Small Cap Research last week set a $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED), in an Opportunity Research report.
Remote Monitoring Portal Feature In POD Model Is Seen Driving Sales
The company has a combination purchase down payment/subscription payment revenue model which provides recurring revenue for sales of its devices. The upbeat forecast by Goldman SmallCap Research is largely based on prior sales of the FDA cleared Wellness Pro Plus. Analyst Rob Goldman wrote that he was especially impressed with the upcoming POD unit’s telemedicine-like portal feature that permits physicians or technicians to monitor in real time and from a remote location how the wearable POD therapy is delivering relief from acute and chronic pain.
Company Has Built A 1,200 Unit Inventory In Preparation For Anticipated Boom In Demand For The Pain-Relieving Devices
For 2021, Matthew Wolfson, CEO, believes that patients who have experienced chronic pain relief from the bioelectronics and electro-modulation delivered by the Wellness Pro Plus devices warrant the investment in the year-end inventory build-up. In anticipation of a rush for the product in early 2021, the company has invested $4.2 Million as it has built and paid for a 1,200+ unit inventory in preparation for attracting hundreds more medical practitioners and distributors in 2021.
The WellnessPlus Pod Seen Debuting In Late 2021, After Anticipated FDA Clearance
Electromedical Technologies, Inc. (OTCQB: EMED) will debut in late 2021 the WellnessPlus POD, a smaller, professional, less costly device that features a special portal for telemedicine-like real time monitoring by physicians. The WellnessPro POD links doctors/technicians and patients with that feature and is less costly, smaller, portable and offers a remote POD portal. The device also provides a unique financial sales structure for the Company, combining a down payment purchase with a recurring monthly subscription services fee.
Source: Stock Market Press
Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.
Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.
Stock Market Press
110 Wall St.
New York, NY 10005 firstname.lastname@example.org Safe Harbor Statement:
Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
See Stock Market Press disclaimer: https://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press